Last updated: February 25, 2026
What is NDC 00378-8043?
NDC 00378-8043 refers to a specific drug product listed under the National Drug Code (NDC) system. It is a proprietary drug, distributed by Novartis, identified as Gleevec (imatinib mesylate), primarily used for treating chronic myeloid leukemia (CML) and certain gastrointestinal stromal tumors (GIST).
Market Landscape
Product Status and Approvals
- Indications: Approved for CML, GIST, and some other cancers.
- Regulatory approvals: FDA approved since 2001 for CML.
- Market exclusivity: Extended due to patent protections until at least 2023, with potential for supplementary patent filings extending exclusivity.
Competitive Environment
The Gleevec market faces competition from:
- Generic imatinib: Launched post-patent expiry, significantly reducing Gleevec's price.
- Other targeted therapies: Including bosutinib, nilotinib, and ponatinib, which are used for resistant CML cases.
- Biosimilars and generics: Gilead’s Iclusig and other biosimilars entering markets where patents expire.
Market Dynamics
- Market size: Estimated at approximately $3.3 billion globally in 2022.
- Growth trend: CAGR of 2% (2022-2027), driven by increasing diagnoses and extension of indications.
- Geographical distribution:
- U.S.: ~55% of revenue
- Europe: ~25%
- Rest of world: ~20%
Pricing Trends
- Brand-name: Gleevec's annual list price in the U.S. was around $146,000 per patient in 2022.
- Post-patent: Generic versions in multiple markets reduced treatment costs by 60-80%, with significant variation based on country and healthcare system.
Price Projections
Short-term (1-2 Years)
Anticipated price decline of 50-70% in developed markets as generic alternatives gain market share:
| Scenario |
Expected Price Range (per 30-day supply) |
Justification |
| Conservative |
$50,000 - $70,000 |
Limited generic penetration, ongoing brand retention |
| Aggressive |
$20,000 - $30,000 |
Rapid generic adoption, market saturation, price competition |
Medium-term (3-5 Years)
The price is expected to stabilize between $15,000 - $25,000, aligned with global biosimilar and generic adoption strategies. Price erosion may slow as patent protections for newer formulations or combination therapies expire.
Long-term (Beyond 5 Years)
Market may see increased penetration of biosimilars, with treatment costs decreasing further to approximately $10,000 - $15,000 per month, especially in countries with cost-controlled healthcare systems.
Revenue Impact and Market Share
- Pre-patent expiry: Gleevec held ~95% of CML treatment market share.
- Post-patent expiry: Share declines to approximately 30-40% due to generics.
- Market share recovery: Limited, with newer targeted therapies and combination treatments capturing segments.
Regulatory and Policy Influence
- Patent litigations and extensions could temporarily shield pricing.
- Health authorities' policies on biosimilars affect market share and pricing.
- Biosimilar entry in Europe and the U.S. remains pivotal for price erosion.
Key Takeaways
- Gleevec remains a critical therapy for CML, but patent expiration drives significant price declines.
- The market faces pressure from generic and biosimilar entrants, reducing revenue potential.
- Short-term pricing will likely see reductions of 50-70%; longer-term prices stabilize at much lower levels.
- Revenue forecasts depend on patent strategies, regulatory landscape, and competitive dynamics.
FAQs
1. When does patent expiry for Gleevec typically occur?
Patent protections are expected to expire around 2023 in the U.S., with supplementary patents possibly extending exclusive rights until 2025 or beyond.
2. How will biosimilar entry impact Gleevec's market?
Biosimilar versions are expected to significantly lower prices, capturing a large market share, particularly in Europe, where biosimilar regulations are more advanced.
3. Are there potential policy changes that could affect pricing?
Yes. Policies favoring biosimilar adoption and price negotiations by health systems can lead to further price reductions.
4. What strategies might Novartis employ to retain market share?
Developing new formulations, expanding indications, and patent strategies can prolong exclusivity and revenue.
5. How does competitive treatment influence price projections?
Emerging therapies for resistant cases or new indications can limit Gleevec's market penetration, affecting pricing and sales volumes.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] FDA. (2022). Gleevec New Drug Application.
[3] EvaluatePharma. (2022). World Market Insights: Oncology Drugs.
[4] US Patent and Trademark Office. (2022). Patent Status for Gleevec.
[5] Deloitte. (2023). Biosimilars and Impact on Pharma Markets.
